Cochrane review finds intermittent fasting no better for weight loss

A new Cochrane review of 22 clinical trials shows that intermittent fasting does not lead to greater weight loss than standard diet advice for overweight or obese adults. The analysis, involving nearly 2,000 participants, challenges the popularity of fasting methods amid rising global obesity rates. Researchers emphasize the need for more long-term studies and personalized approaches.

Obesity has become a pressing public health issue, with the World Health Organization noting that adult obesity rates have tripled since 1975. In 2022, approximately 2.5 billion adults were overweight, including 890 million living with obesity.

Intermittent fasting, popularized through social media and wellness trends, involves strategies like alternate-day fasting, periodic fasting, and time-restricted feeding. However, a Cochrane review published in 2026 examined 22 randomized clinical trials with 1,995 adults from regions including North America, Europe, China, Australia, and South America. Most trials lasted up to one year.

The review found no clinically meaningful difference in weight loss between intermittent fasting and conventional diet advice or no intervention at all. Side effects were not consistently reported, limiting assessments of risks. The studies primarily involved white participants from high-income countries, highlighting gaps in research for diverse populations.

"Intermittent fasting just doesn't seem to work for overweight or obese adults trying to lose weight," stated Luis Garegnani, lead author from the Universidad Hospital Italiano de Buenos Aires Cochrane Associate Centre. He added, "Intermittent fasting may be a reasonable option for some people, but the current evidence doesn't justify the enthusiasm we see on social media."

The lack of long-term data poses challenges, as obesity is a chronic condition. "Obesity is a chronic condition. Short-term trials make it difficult to guide long-term decision-making for patients and clinicians," Garegnani noted.

Senior author Eva Madrid from the Cochrane Evidence Synthesis Unit Iberoamerica remarked, "With the current evidence available, it's hard to make a general recommendation. Doctors will need to take a case-by-case approach when advising an overweight adult on losing weight."

The authors suggest results may vary by factors such as sex, age, ethnicity, medical conditions, or eating behaviors, calling for further research in low- and middle-income countries.

Relaterede artikler

Relieved Crohn's patients in Stanford clinic with fasting-mimicking diet calendar, healthy meals, and positive trial results charts.
Billede genereret af AI

Five-day monthly fasting-mimicking diet eased symptoms and inflammation in Crohn’s trial

Rapporteret af AI Billede genereret af AI Faktatjekket

A Stanford Medicine-led randomized trial in the United States found that a five-day-per-month fasting-mimicking diet was linked to improved patient-reported symptoms and lower biological markers of inflammation in adults with mild-to-moderate Crohn’s disease. The results were published in Nature Medicine.

A new review of studies suggests that intermittent fasting offers no significant advantage over traditional dieting or no intervention for weight loss among overweight or obese adults. Researchers analyzed data from 22 trials involving nearly 2,000 participants. While the approach remains popular, experts highlight limitations in the evidence.

Rapporteret af AI

A new study from Northwestern Medicine indicates that stopping eating three hours before bed and extending overnight fasting can improve blood pressure, heart rate, and blood sugar control without reducing calorie intake. Participants aligned their eating with natural sleep cycles, leading to measurable cardiometabolic benefits. The research highlights the importance of meal timing relative to sleep.

A randomized controlled trial in 180 adults found that prescribing diets high, regular or low in sweet-tasting foods for six months did not change participants’ liking for sweet taste, body weight, energy intake, or several biomarkers linked to diabetes and cardiovascular disease. The researchers concluded the results do not support public health advice that aims to reduce exposure to sweet-tasting foods regardless of whether sweetness comes from sugar, low-calorie sweeteners, fruit or dairy.

Rapporteret af AI Faktatjekket

A randomized, placebo-controlled trial led by Australia’s Garvan Institute of Medical Research found that metformin, a long-used and low-cost drug for type 2 diabetes, did not improve clamp-measured insulin resistance in adults with type 1 diabetes but was associated with roughly 12% lower insulin requirements while blood sugar measures remained broadly unchanged.

En ny undersøgelse afslører, at personer med alvorlig fedme står over for en markant højere risiko for alvorlige eller dødelige infektioner. Baseret på data fra over 540.000 individer i Storbritannien og Finland er risikoen for fedme grad 3 tre gange højere end for normalvægtige. Forskere advarer om stigende globale fedme-rater.

Rapporteret af AI

En ny undersøgelse fra University of Gothenburg viser, at tirzepatid, det aktive stof i diabetes- og vægttabsmedicin Mounjaro, reducerer alkoholindtag og tilbagefaldslignende adfærd hos rotter og mus. Dette bygger på tidligere forskning om semaglutid i Ozempic og Wegovy, som dæmper alkoholforbrug hos mennesker. Forskere håber på lignende effekter hos patienter med alkoholafhængighed.

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis